NVIV - InVivo Therapeutics Holdings Corp.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4801
+0.0300 (+6.67%)
At close: 3:38PM EDT
Stock chart is not supported by your current browser
Previous Close0.4501
Open0.4500
Bid0.4510 x 1400
Ask0.4800 x 1100
Day's Range0.4327 - 0.4801
52 Week Range0.4200 - 2.7500
Volume49,201
Avg. Volume36,932
Market Cap4.471M
Beta (3Y Monthly)0.68
PE Ratio (TTM)N/A
EPS (TTM)-1.2960
Earnings DateNov 6, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • Business Wire

    InVivo Therapeutics Announces Adjournment of Annual Meeting

    InVivo Therapeutics Holdings Corp. (NVIV) today announced that its 2019 Annual Meeting of Stockholders, scheduled for June 11, 2019, was convened and adjourned without any business being conducted due to the fact that quorum was not achieved. The Annual Meeting will be reconvened July 2, 2019 to allow more opportunity for stockholders to vote on all proposals described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (SEC) on April 25, 2019. It has come to the Company’s attention that certain stockholders may have been unable to vote their shares through their broker or financial institutions, particularly if such shares are held through European institutions.

  • Business Wire

    InVivo Therapeutics Announces Enrollment of First Two Patients into the INSPIRE 2.0 Study for the Treatment of Acute Spinal Cord Injury

    InVivo Therapeutics Holdings Corp. (NVIV) today announced that the first two patients have been enrolled into The INSPIRE 2.0 Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury). “Having the first two patients enrolled into the INSPIRE 2.0 Study is a critical milestone for the company and for the spinal cord injury patient population, as there continues to be inadequate treatment options for these patients. With eight clinical sites now open for enrollment, we remain optimistic about continuing to execute on the INSPIRE 2.0 study and will provide updates when appropriate,” commented Richard Toselli, M.D., President and Chief Executive Officer of InVivo.

  • Business Wire

    InVivo Therapeutics Announces Presentation of Twelve-Month Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord Injury

    InVivo Therapeutics Holdings Corp. (NVIV) (“InVivo” or the “Company”) today announced the presentation of the twelve-month results from the company’s single-arm INSPIRE study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury). The findings were presented at the 2019 AANS Meeting in San Diego, CA through an e-poster titled, “Twelve Month Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord Injury”, co-authored by Kee Kim, M.D., Department of Neurosurgery, UC-Davis, Sacramento, CA, K. Stuart Lee, M.D., Division of Neurosurgery, Vidant Health, Greenville, NC, Lee, Domagoj Coric, M.D., Carolina Neurosurgery and Spine, Charlotte, NC, Nicholas Theodore M.D., Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, and Richard Toselli, M.D., President and Chief Executive Officer of InVivo.

  • Business Wire

    InVivo Therapeutics Reports 2018 Year-end Financial Results and Provides Business Update

    InVivo Therapeutics Holdings Corp. today reported financial results for the year ended December 31, 2018.

  • Business Wire

    InVivo Therapeutics Announces Appointment of Richard Christopher as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    InVivo Therapeutics Holdings Corp. (NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries (SCIs), today announces the appointment of Richard Christopher as its Chief Financial Officer and Treasurer, effective January 14, 2019. Prior to joining InVivo, Mr. Christopher was the Chief Financial Officer of iCAD, Inc., a Nasdaq-listed company with a focus on therapies and solutions for the early identification and treatment of cancer. Prior to iCAD, Inc., Mr. Christopher was Chief Financial Officer and Chief Operating Officer of Caliber Imaging & Diagnostics, Inc., a medical technology company focused on cancer detection imaging solutions, with primary applications in dermatology.

  • GlobeNewswire

    Report: Developing Opportunities within Command Center, Neurotrope, Selecta Biosciences, InVivo Therapeutics, SeaSpine, and Senestech — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Associated Press

    InVivo: 3Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 42 cents. In the final minutes of trading on Thursday, the company's shares hit $2.09. A year ago, they were trading ...